<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823299</url>
  </required_header>
  <id_info>
    <org_study_id>v21022021</org_study_id>
    <nct_id>NCT04823299</nct_id>
  </id_info>
  <brief_title>Patient Specific Ablation Strategy for Atrial Fibrillation (AWARE-2): A Randomized Clinical Trial</brief_title>
  <acronym>AWARE-2</acronym>
  <official_title>Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Cryoablation Pulmonary Vein Isolation- Patient Specific Precise Approach to Paroxysmal Atrial Fibrillation Ablation AWARE-2 - Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial Fibrillation (AF) is a heart rhythm disturbance that affects over a million people in&#xD;
      North America. AF can cause strokes, heart failure, poor quality of life and may lead to&#xD;
      premature death. Catheter ablation has been shown to be superior to medications for symptoms,&#xD;
      prevention of stroke and heart failure. AF recurrence is a problem after catheter ablation.&#xD;
      Our research has found that in most cases AF recurrence occurs because the catheter procedure&#xD;
      was ineffective. The objective of our clinical trial is to find out if a new method of&#xD;
      performing the catheter procedure will be more effective in preventing AF recurrence compared&#xD;
      to the current standard of care ablation procedure. Subjects will be randomly allocated to&#xD;
      undergo either the standard of care ablation, or the novel patient tailored ablation. The&#xD;
      novel method aims to understand the unique factors responsible for AF in each individual and&#xD;
      uses this information to perform a patient-tailored catheter ablation procedure. This is&#xD;
      expected to improve the results of AF ablation. The effectiveness and safety of the ablation&#xD;
      procedure will be specifically evaluated in women to understand the effect of sex on AF&#xD;
      ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Catheter ablation (CA) for paroxysmal atrial fibrillation (AF) is beset by the significant&#xD;
      limitation of recurrent AF in one third of subjects. Subjects with recurrence of AF usually&#xD;
      require repeat ablation procedures with the attendant risk of potentially serious&#xD;
      complications and significant costs to the health care system. We hypothesize that an&#xD;
      innovative, a patient specific precise CA strategy will significantly reduce AF recurrence.&#xD;
&#xD;
      This study will determine whether a precise, patient specific ablation strategy (tailored to&#xD;
      the patient's triggers and substrate) combining electrophysiological (EPS) testing guided&#xD;
      radiofrequency catheter ablation (RFA) for pulmonary vein isolation (PVI) using the wide-area&#xD;
      circumferential (WACA) technique along with non-pulmonary vein trigger (NPVT) and low-voltage&#xD;
      area (LVA) ablation will improve freedom from recurrent atrial fibrillation (AF) when&#xD;
      compared to PVI alone strategy using cryoballoon ablation (CAB).&#xD;
&#xD;
      The PVI-WACA technique has a 'ceiling effect' due to PV reconnection, especially along the&#xD;
      posterior wall of the LA as shown in an observational study investigating the pattern of PV&#xD;
      reconnection from our institution. Further attempts at improving durable PVI rates with&#xD;
      higher energy ablation may not be possible due to concerns regarding esophageal injury and&#xD;
      development of atrio-esophageal fistula. It may be possible to improve the results of CA for&#xD;
      paroxysmal AF by targeting NPVT and LVA that are not usually targeted during CA using the&#xD;
      PVI-WACA only strategy.&#xD;
&#xD;
      This trial is a single-blinded (subjects blinded), prospective, parallel arm RCT. Subjects&#xD;
      satisfying the inclusion and exclusion criteria will be randomized (1:1) to either the&#xD;
      control arm (cryoballoon ablation) or the experimental arm (RF based WACA ±&#xD;
      electrophysiological testing guided ablation of non-PV triggers of AF and low voltage area&#xD;
      ablation). Randomization will be conducted after informed consent has been obtained and&#xD;
      before catheter ablation. The first 60 days after catheter ablation will be considered a&#xD;
      &quot;blanking-period&quot; and atrial tachyarrhythmias (AF, Atrial Flutter [AFl] or Atrial Tachycardia&#xD;
      [AT]) occurring during this period will be documented. However, these will not be considered&#xD;
      treatment failures. Subject accrual will occur over a 36-month period and each subject will&#xD;
      have a minimum follow-up period of 24 months, with a total trial duration of 60-months.&#xD;
      Subjects will be followed up at 2,6,12,18 and 24 months after ablation, with an implantable&#xD;
      loop recorder (ILR) interrogation. Quality of life questionnaires (EQ-5D, AFEQT&#xD;
      questionnaires and CCS-SAF scale) will be administered at baseline,12-months and 24 months&#xD;
      post ablation visit. A tool to assist in decision making will be administered to subjects&#xD;
      during the consent process.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-blind, prospective, randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant only blinded to the treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from atrial fibrillation, atrial flutter or atrial tachycardia</measure>
    <time_frame>61 to 365 days after ablation</time_frame>
    <description>AF, AFl or AT, symptomatic or asymptomatic lasting ≥ 30 seconds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation burden</measure>
    <time_frame>760 days</time_frame>
    <description>Total duration of AF recorded on ambulatory monitoring/total duration of monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term rate of documented AF, AFl or AT</measure>
    <time_frame>760 days</time_frame>
    <description>Long-term rate of documented AF, AFl or AT lasting ≥ 30 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any ECG/ILR documented AF, AFl or AT</measure>
    <time_frame>First 60 days after catheter ablation</time_frame>
    <description>Incidence of any ECG/ILR documented AF, AFl or AT (symptomatic or asymptomatic; lasting ≥ 30 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ablation procedure duration</measure>
    <time_frame>On day of ablation</time_frame>
    <description>Catheter ablation procedure time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopic exposure</measure>
    <time_frame>On day of ablation</time_frame>
    <description>Total Air Kerma (mGy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopic exposure dose</measure>
    <time_frame>On day of ablation</time_frame>
    <description>Dose Area Protocol (Gy.cm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Related Complications</measure>
    <time_frame>760 days</time_frame>
    <description>Stroke, PV stenosis, pericarditis, phrenic nerve palsy, cardiac perforation, atrio-esophageal fistula, major bleeding and/or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency room visits or hospitalization due to recurrent AF, AFl or AT</measure>
    <time_frame>760 days</time_frame>
    <description>Emergency room visits or hospitalization due to recurrent AF, AFl or AT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat catheter ablation for AF, AFl or AT</measure>
    <time_frame>760 days</time_frame>
    <description>Repeat catheter ablation for AF, AFl or AT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scale</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>AFEQT questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life SAF scale</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>CCS-SAF scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Catheter Ablation</condition>
  <condition>Radiofrequency Catheter Ablation</condition>
  <arm_group>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cryoballoon Pulmonary Vein Isolation-Wide area circumferential ablation (WACA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RF based WACA ± EP testing guided ablation of non-PV triggers of AF and low voltage area ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiofrequency wide area circumferential ablation (WACA) ± electrophysiological testing guided ablation of non-pulmonary vein triggers of AF and low voltage area ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoballoon ablation</intervention_name>
    <description>Cryoballoon pulmonary vein isolation ablation</description>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency catheter ablation +EPS guided trigger and substrate ablation</intervention_name>
    <description>RF based WACA ± electrophysiological testing guided ablation of non-PV triggers of AF and low voltage area ablation</description>
    <arm_group_label>RF based WACA ± EP testing guided ablation of non-PV triggers of AF and low voltage area ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years on the date of consent for the trial.&#xD;
&#xD;
          2. Subjects must have Paroxysmal AF with at least two episodes of AF over the past 12&#xD;
             months; Early Persistent AF- at least two episodes of AF.&#xD;
&#xD;
          3. At least one episode of AF documented on 12-lead ECG, Holter monitor, Trans-&#xD;
             telephonic monitor (TTM) or Loop Recorder.&#xD;
&#xD;
          4. Subjects must be able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Persistent and permanent AF&#xD;
&#xD;
          2. History of previous catheter or surgical ablation for AF, AFl, AT, AVNRT, AVRT.&#xD;
&#xD;
          3. Documented AVNRT, AVRT, AT or Atrial Flutter prior to enrolment in the trial.&#xD;
&#xD;
          4. Previous left atrial (LA) ablation or LA surgery.&#xD;
&#xD;
          5. Previous pulmonary vein stenosis or pulmonary vein stent.&#xD;
&#xD;
          6. Pre-existing hemi-diaphragmatic paralysis.&#xD;
&#xD;
          7. Active intracardiac thrombus.&#xD;
&#xD;
          8. Contraindication to systemic oral anticoagulation therapy or radiocontrast materials.&#xD;
&#xD;
          9. Current immunosuppressant therapy (corticosteroids, biologic immunomodulators; such&#xD;
             patients may be considered if they can safely discontinue immunosuppressants for three&#xD;
             months prior to and for three months following catheter ablation).&#xD;
&#xD;
         10. Reversible causes of AF (eg. uncontrolled hyperthyroidism, within six months of&#xD;
             cardiac surgery).&#xD;
&#xD;
         11. Left ventricular ejection fraction &lt;35%.&#xD;
&#xD;
         12. NYHA Class 3-4 heart failure.&#xD;
&#xD;
         13. Hypertrophic cardiomyopathy with septal or posterior LV wall thickness of &gt;1.8 cm.&#xD;
&#xD;
         14. Significant valve disease (moderate or severe mitral/aortic stenosis or&#xD;
             regurgitation).&#xD;
&#xD;
         15. Known adverse reaction to adenosine.&#xD;
&#xD;
         16. Significant chronic kidney disease (eGFR &lt;30ml/min/1.73m2).&#xD;
&#xD;
         17. Significant congenital heart disease (including atrial septal defects or pulmonary&#xD;
             vein abnormalities; however, subjects with patent foramen ovale will not be excluded).&#xD;
&#xD;
         18. Pregnant subjects.&#xD;
&#xD;
         19. Cerebral ischemic event (stroke or transient ischemic attack) in the six months prior&#xD;
             to consenting for the trial.&#xD;
&#xD;
         20. Life expectancy less than one-year.&#xD;
&#xD;
         21. Currently participating or anticipated to participate in clinical trials of drug,&#xD;
             device or biologic agents that could affect the results of this trial.&#xD;
&#xD;
         22. Unwilling or unable to comply fully with study procedures and follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Girish Nair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Girish Nair, MD</last_name>
    <phone>613-696-7272</phone>
    <email>GNair@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tammy Knight</last_name>
    <phone>613-696-7000</phone>
    <phone_ext>19808</phone_ext>
    <email>TKnight@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Girish Nair, MD</last_name>
      <email>GNair@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Girish Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Vidal Essebag, MD</last_name>
      <email>vidal.essebag@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Vidal Essebag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

